top of page
Our Blog
See below for an opinion on current matters around the world.
Search


Costs and benefits: how has the Pharmaceutical Benefits Scheme contributed to Australia over the last quarter century?
Brendan Shaw How much value for money does Australia get from the Pharmaceutical Benefits Scheme? Following on from an earlier blog ...
Brendan Shaw
Mar 258 min read
110 views
0 comments


Recognising rebates: the role of pharmaceutical companies in funding UK and Australian pharmaceutical schemes
Brendan Shaw and Vinh Vo The United Kingdom and Australia have a long tradition of mostly friendly rivalry over things like cricket and...
Brendan Shaw
Feb 257 min read
128 views
0 comments


The Good, the Bad, and the Ugly: Australia’s HTA Review Final Report
Brendan Shaw "The HTA Review Report is farsighted enough to be visionary, while being firmly grounded in the practicalities of the here...
Brendan Shaw
Nov 13, 20247 min read
253 views
0 comments


Déjà vu all over again?: Australia’s industrial policy debate
Brendan Shaw “Although it is portrayed as a forward-looking approach to industry policy, there is much that is “old‑think” about it … the...
Brendan Shaw
Nov 15, 20238 min read
96 views
0 comments

Pharmaceuticals Take Centre Stage in Australian Election Campaign
Brendan Shaw Article on the 2022 Australian national election campaign published on 25 May in PharmaBoardroom. The article examines the...
Brendan Shaw
May 24, 20221 min read
20 views
0 comments


Will she be right?: the ‘non-issues’ of the 2022 Australian federal election
Brendan Shaw As Australia is about to undergo its three-yearly ritual of a national election later this month, I am struck by the number...
Brendan Shaw
May 8, 20229 min read
409 views
0 comments


Australians now understand there is a 'queue' for new health technologies
Podcast interview of Brendan Shaw with Paul Cross from BioPharmaDispatch, 8 December 2021 that can be heard here. The interview discusses...
Brendan Shaw
Dec 8, 20211 min read
33 views
0 comments


Medicines Australia Strategic Agreement is 'the end of the beginning'
Brendan Shaw Article published on 21 September 2021 in BioPharmaDispatch on the 2021 Strategic Agreement signed between the Australian...
Brendan Shaw
Sep 21, 20211 min read
14 views
0 comments


NICE methods review, UK Life Sciences Strategy and the life sciences industry: lessons for Australia
Brendan Shaw “We must balance ensuring the NHS gets the best value, delivering improved patient access and promoting innovation. These...
Brendan Shaw
Sep 11, 20216 min read
132 views
0 comments


Fair dinkum or collywobbles? Life sciences and the Australia – UK free trade agreement
Brendan Shaw “Fair dinkum – (adj, Australian informal), true, genuine, authentic” - Aussie Slang Dictionary “Collywobbles – (noun, UK...
Brendan Shaw
Jun 17, 20215 min read
102 views
1 comment


Opportunities for the Life Science Industry in Australia post-COVID
Brendan Shaw Article published 24 May 2021 on opportunities for Australia's life science sector in a post-COVID world can be found here....
Brendan Shaw
May 24, 20211 min read
10 views
0 comments


More risk for government this time around in agreement negotiation
Brendan Shaw Article published in BioPharmaDispatch 9 April 2021 on the risks for government and industry in negotiations on a new...
Brendan Shaw
Apr 8, 20211 min read
9 views
0 comments


The next 20-year PBS agenda: government commitments to new medicines spending
Brendan Shaw If it's real and if it sticks, the Australian government’s ‘New Medicines Funding Guarantee’ will be a significant...
Brendan Shaw
Oct 14, 20203 min read
129 views
0 comments


PBS New Medicines Funding Guarantee: echoes of elections past ...
Brendan Shaw Article published in BiopharmaDispatch on 13 October 2020 on the Australian Government's 2020 Budget announcement on funding...
Brendan Shaw
Oct 13, 20201 min read
21 views
0 comments


This could get messy: Trump’s New ‘Most Favoured Nation’ Executive Order on Medicine Pricing
Brendan Shaw Article published 24 September 2020 in PharmaBoardroom on US President Donald Trump's new Executive Order on Most Favoured...
Brendan Shaw
Sep 23, 20201 min read
27 views
0 comments


When profit isn’t everything: 46,000 years of cultural history vs the iron ore spot price
Brendan Shaw “Our people are deeply troubled and saddened by the destruction of these rock shelters and are grieving the loss of...
Brendan Shaw
Jun 3, 20205 min read
214 views
0 comments


What trade war?: Western and Chinese life science companies just get on with it
"When the winds of change blow, some people build walls and others build windmills" - Chinese proverb There’s been a lot said about the...
Brendan Shaw
Dec 4, 20195 min read
38 views
0 comments


Australia's National Medicines Policy is outdated and in need of review
Article published with Associate Professor Orin Chisholm from the University of New South Wales on 22 July 2019 in the Medical Journal of...
Brendan Shaw and Orin Chisholm
Jul 23, 20191 min read
15 views
0 comments


A minor issue?: minor parties and independents in the 2019 Australian election
There’s so much coming out of last weekend’s 2019 Australian federal election that pundits will be writing about it for months. But there...
Brendan Shaw
May 23, 20194 min read
236 views
0 comments


UK-Australia trade deal an opportunity for life sciences in both countries
Article published on PharmaTimes online can be found here. #Australia #UnitedKingdom #Brexit #Britain #trade #industrialpolicy...
Brendan Shaw
Apr 24, 20181 min read
13 views
0 comments
bottom of page